Dimitrios Farmakiotis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1671718/publications.pdf

Version: 2024-02-01

96 papers 3,954 citations

218592 26 h-index 60 g-index

98 all docs 98 docs citations 98 times ranked 8060 citing authors

#	Article	IF	CITATIONS
1	Use of anti-spike monoclonal antibodies in kidney transplant recipients with COVID-19: Efficacy, ethnic and racial disparities. American Journal of Transplantation, 2022, 22, 640-645.	2.6	30
2	Elevated Tacrolimus Levels at Time of Diagnosis of COVID-19 Compared to Baseline Among Hospitalized Organ Transplant Recipients. Annals of Pharmacotherapy, 2022, 56, 1197-1202.	0.9	1
3	Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study. Open Forum Infectious Diseases, 2022, 9, ofac037.	0.4	8
4	COVID-19 Treatments for Nonhospitalized Patients. JAMA - Journal of the American Medical Association, 2022, 327, 2247.	3.8	4
5	Singleâ€enter experience with nirmatrelvir/ritonavir in kidney transplant recipients on tacrolimus maintenance immunosuppression. Clinical Transplantation, 2022, 36, .	0.8	6
6	Call for Action: Racial Disparities in Clinical Research. Clinical Infectious Diseases, 2021, 73, 356-357.	2.9	4
7	Antifungal prophylaxis during 7 + 3 induction chemotherapy for acute myeloid leukemia is associated with improved survival, in a setting with low incidence of invasive mold infections. Supportive Care in Cancer, 2021, 29, 707-712.	1.0	5
8	Acute Necrotizing Pneumonia from Herpes Simplex Virus. American Journal of Medicine, 2021, 134, e121-e122.	0.6	2
9	Validation of pneumonia prognostic scores in a statewide cohort of hospitalised patients with COVIDâ€19. International Journal of Clinical Practice, 2021, 75, e13926.	0.8	18
10	Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR. Leukemia Research, 2021, 100, 106473.	0.4	3
11	Successful recovery from COVIDâ€19 in three kidney transplant recipients who received convalescent plasma therapy. Transplant Infectious Disease, 2021, 23, e13451.	0.7	30
12	Coronavirus Disease 2019 in Kidney Transplant Recipients: Single-Center Experience and Case-Control Study. Transplantation Proceedings, 2021, 53, 1187-1193.	0.3	8
13	Use of antibiotics is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis. International Journal of Infectious Diseases, 2021 , 106 , $142-154$.	1.5	46
14	Predictors of severity and mortality among patients hospitalized with COVID-19 in Rhode Island. PLoS ONE, 2021, 16, e0252411.	1.1	12
15	A eulogy for Dr Francisco Miguel Marty Forero. Transplant Infectious Disease, 2021, 23, e13645.	0.7	O
16	Care without a compass: Including patients with cancer in COVID-19 studies. Cancer Cell, 2021, 39, 895-896.	7.7	14
17	Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease. Blood Advances, 2021, 5, 54-60.	2.5	11
18	Low-Dose Valganciclovir Prophylaxis Is Safe and Cost-Saving in CMV-Seropositive Kidney Transplant Recipients. Progress in Transplantation, 2021, 31, 368-376.	0.4	2

#	Article	IF	CITATIONS
19	Comparison of COVID-19 outcomes in organ transplant recipients (OTr) and non-transplant patients: a study protocol for rapid review. Systematic Reviews, 2021, 10, 299.	2.5	1
20	39. Anti-Spike Monoclonal Antibody Therapy for Kidney Transplant Recipients with COVID-19. Open Forum Infectious Diseases, 2021, 8, S28-S29.	0.4	0
21	The Human Microbiome and Checkpoint Inhibition: Potential Benefits From Antibiotic Stewardship. Clinical Infectious Diseases, 2020, 71, 701-702.	2.9	2
22	Invasive Pulmonary Aspergillosis in Patients with SARS-CoV-2 Infection: A Systematic Review of the Literature. Diagnostics, 2020, 10, 807.	1.3	49
23	SARSâ€CoVâ€2 and HIV coinfection: clinical experience from Rhode Island, United States. Journal of the International AIDS Society, 2020, 23, e25573.	1.2	57
24	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discovery, 2020, 10, 1514-1527.	7.7	108
25	Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience. Open Forum Infectious Diseases, 2020, 7, ofaa319.	0.4	16
26	A kidney transplant recipient with nausea, vomiting, and diarrhea after a recent COVIDâ€19 exposure. American Journal of Transplantation, 2020, 20, 2618-2620.	2.6	1
27	Fatal Mucormycosis and Aspergillosis in an Atypical Host: What Do We Know about Mixed Invasive Mold Infections?. Case Reports in Infectious Diseases, 2020, 2020, 1-6.	0.2	5
28	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell, 2020, 38, 761-766.	7.7	26
29	Hyperammonemia syndrome due to Ureaplasma urealyticum in a kidney transplant recipient: A case of disseminated disease from a fluoroquinoloneâ€resistant isolate. Transplant Infectious Disease, 2020, 22, e13328.	0.7	9
30	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	6.3	1,395
31	CMV cell–mediated immunity assays: Focus on CD4+ cells. American Journal of Transplantation, 2020, 20, 2285-2286.	2.6	2
32	Impact of Infectious Disease Consultation in Patients With Candidemia: A Retrospective Study, Systematic Literature Review, and Meta-analysis. Open Forum Infectious Diseases, 2020, 7, ofaa270.	0.4	26
33	Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events. BMC Infectious Diseases, 2020, 20, 58.	1.3	28
34	Successful Kidney Transplantation in a Recipient Coinfected with Hepatitis C Genotype 2 and HIV from a Donor Infected with Hepatitis C Genotype 1 in the Direct-Acting Antiviral Era. Case Reports in Hepatology, 2020, 2020, 1-6.	0.4	1
35	530. COVID-19 in kidney transplant recipients: Single-center experience and case-control study. Open Forum Infectious Diseases, 2020, 7, S332-S332.	0.4	0
36	749. Impact of Infectious Disease Consultation in Patients with Candidemia: A Retrospective study, Systematic Literature Review and Meta-analysis. Open Forum Infectious Diseases, 2020, 7, S421-S422.	0.4	0

#	Article	IF	Citations
37	576. Half-dose Valganciclovir Prophylaxis is Safe and Cost-effective in CMV Seropositive Renal Transplant Recipients. Open Forum Infectious Diseases, 2020, 7, S352-S353.	0.4	1
38	191. The impact of antibiotic use on clinical outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Open Forum Infectious Diseases, 2020, 7, S101-S101.	0.4	0
39	Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine. Clinical Infectious Diseases, 2019, 68, 247-255.	2.9	42
40	A Man With Headache, Fever, and Neck Stiffness. JAMA - Journal of the American Medical Association, 2019, 321, 1624.	3.8	0
41	Bloodstream Infections in Continuous Flow Left Ventricular Assist Device Recipients: Diagnostic and Clinical Implications. ASAIO Journal, 2019, 65, 798-805.	0.9	11
42	False positive bronchoalveolar lavage galactomannan: Effect of host and cutâ€off value. Mycoses, 2019, 62, 204-213.	1.8	20
43	Candidemia in Adults at a Tertiary Hospital in China: Clinical Characteristics, Species Distribution, Resistance, and Outcomes. Mycopathologia, 2018, 183, 679-689.	1.3	17
44	Rapid Reversal of Complete Binocular Blindness With High-Dose Corticosteroids and Lumbar Drain in a Solid Organ Transplant Recipient With Cryptococcal Meningitis and Immune Reconstitution Syndrome: First Case Study and Literature Review. Open Forum Infectious Diseases, 2018, 5, ofy007.	0.4	3
45	2082. Using a Commercially Available Assay Measuring Cytomegalovirus (CMV)-Specific CD4+ and CD8+T-Cell Immunity by Intracellular Cytokine Staining to Predict Clinically Significant CMV Events. Open Forum Infectious Diseases, 2018, 5, S609-S609.	0.4	O
46	Disseminated Mucormycosis with Positive <i>Aspergillus</i> Galactomannan. Case Reports in Infectious Diseases, 2018, 2018, 1-3.	0.2	5
47	Brucellosis in Adults and Children: A 10-Year Case Series at Two Large Academic Hospitals in Houston, Texas. Southern Medical Journal, 2018, 111, 324-327.	0.3	7
48	Pruritic Rash in a Patient with Hodgkin's Lymphoma. Cureus, 2018, 10, e2450.	0.2	2
49	Rhomboid glossitis in disseminated CMV infection. IDCases, 2017, 8, 42-44.	0.4	1
50	Epidemiology of antifungal resistance in human pathogenic yeasts: current viewpoint and practical recommendations for management. International Journal of Antimicrobial Agents, 2017, 50, 318-324.	1.1	58
51	Frequent False-positive Bronchoalveolar Lavage Galactomannan Values in a Real-world Setting. Open Forum Infectious Diseases, 2017, 4, S611-S611.	0.4	O
52	Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	10
53	Updated practice guidelines for the diagnosis and management of aspergillosis: challenges and opportunities. Journal of Thoracic Disease, 2016, 8, E1767-E1770.	0.6	2
54	Epidemiology of Candidemia in Hospitalized Patients With Acute Leukemia in the Absence of Routine Antifungal Prophylaxis. Open Forum Infectious Diseases, 2016, 3, .	0.4	3

#	Article	IF	CITATIONS
55	Initial Treatment of Cancer Patients with Fluconazole-Intermediate C. glabrata Fungemia With an Echinocandin or Polyene is Associated With Better Survival Than Initial Treatment With an Azole. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
56	Infectious Complications Associated with Bendamustine Exposure in Patients with Indolent non-Hodgkin Lymphoma. Open Forum Infectious Diseases, $2016,3,.$	0.4	0
57	Time-to-reporting of blood culture positivity and central venous catheter-associated Candida glabrata fungemia in cancer patients. Diagnostic Microbiology and Infectious Disease, 2016, 85, 391-393.	0.8	4
58	Metronidazole-Associated Encephalopathy. New England Journal of Medicine, 2016, 374, 1465-1465.	13.9	17
59	Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. Nature Communications, 2016, 7, 11128.	5.8	227
60	<i>Candida</i> spp. airway colonization: A potential risk factor for <i>Acinetobacter baumannii</i> ventilator-associated pneumonia. Medical Mycology, 2016, 54, 557-566.	0.3	30
61	Candida albicans Airway Colonization Facilitates Subsequent Acinetobacter baumannii Pneumonia in a Rat Model. Antimicrobial Agents and Chemotherapy, 2016, 60, 3348-3354.	1.4	17
62	Mucormycoses. Infectious Disease Clinics of North America, 2016, 30, 143-163.	1.9	162
63	Utility of in-house fluconazole disk diffusion susceptibility testing in the treatment of candidemia. Diagnostic Microbiology and Infectious Disease, 2016, 84, 223-226.	0.8	0
64	An Avid Imitator. Journal of Clinical Medicine Research, 2016, 8, 257-259.	0.6	0
65	Uncommon <i>Candida</i> Species Fungemia among Cancer Patients, Houston, Texas, USA. Emerging Infectious Diseases, 2015, 21, 1942-50.	2.0	87
66	The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. Journal of Antimicrobial Chemotherapy, 2015, 70, 2362-2368.	1.3	67
67	Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit from infectious disease consultation. Clinical Microbiology and Infection, 2015, 21, 79-86.	2.8	82
68	Temporal Trends in Stem Cell Transplant and Hematologic Malignancy Patients With Mucormycosis, 2001–2014. Open Forum Infectious Diseases, 2015, 2, .	0.4	1
69	Diagnostic Value of Eosinopenia in Non-Typhi Salmonella Enteritis. Clinical Infectious Diseases, 2014, 59, 1197-1198.	2.9	2
70	1446Fungemia due to Uncommon Candida species in Patients with Cancer: Increasing Incidence, Frequent Resistance and High Mortality rates. Open Forum Infectious Diseases, 2014, 1, S380-S381.	0.4	0
71	Drug-ResistantCandida glabrataInfection in Cancer Patients. Emerging Infectious Diseases, 2014, 20, 1833-40.	2.0	127
72	Efficacy and Tolerability of Micafungin Monotherapy for Candidemia and Deep-Seated Candidiasis in Adults with Cancer. Antimicrobial Agents and Chemotherapy, 2014, 58, 3526-3529.	1.4	8

#	Article	IF	CITATIONS
73	Diet Modification and Metformin Have a Beneficial Effect in a Fly Model of Obesity and Mucormycosis. PLoS ONE, 2014, 9, e108635.	1.1	26
74	Typhoid Fever in an Inner City Hospital: A 5‥ear Retrospective Review. Journal of Travel Medicine, 2013, 20, 17-21.	1.4	28
75	The diagnostic yield of skin biopsy in patients with leukemia and suspected infection. Journal of Infection, 2013, 67, 265-272.	1.7	12
76	The Safety of Amphotericin B Lipid Complex in Patients With Prior Severe Intolerance to Liposomal Amphotericin B. Clinical Infectious Diseases, 2013, 56, 701-703.	2.9	13
77	Obesity and Serious Infections. Annals of Internal Medicine, 2013, 159, 859.	2.0	3
78	The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia. Fertility and Sterility, 2009, 91, 1427-1430.	0.5	22
79	Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients. Fertility and Sterility, 2009, 92, 2078-2081.	0.5	14
80	Low protein Z levels, but not the intron F G79A polymorphism, are associated with unexplained pregnancy loss. Thrombosis Research, 2009, 124, 24-27.	0.8	21
81	Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clinical Endocrinology, 2008, 69, 279-284.	1.2	31
82	Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertility and Sterility, 2008, 89, 899-906.	0.5	97
83	Plasma visfatin levels in normal weight women with polycystic ovary syndrome. European Journal of Internal Medicine, 2008, 19, 406-412.	1.0	51
84	The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis, 2008, 196, 958-965.	0.4	44
85	The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters in men with idiopathic oligozoospermia. Fertility and Sterility, 2007, 88, 847-853.	0.5	20
86	Ghrelin Serum Levels During Oral Glucose Tolerance Test in Prepubertal Obese Children with Insulin Resistance. Journal of Pediatric Endocrinology and Metabolism, 2007, 20, 1085-92.	0.4	8
87	Childhood acute pyelonephritis: comparison of power Doppler sonography and Tc-DMSA scintigraphy. Pediatric Radiology, 2007, 37, 685-690.	1.1	26
88	Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome. Fertility and Sterility, 2006, 85, 1778-1783.	0.5	80
89	Creatine phosphokinase in ectopic pregnancy revisited: Significant diagnostic value of its MB and MM isoenzyme fractions. American Journal of Obstetrics and Gynecology, 2006, 194, 86-91.	0.7	19
90	Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls. Human Reproduction, 2005, 20, 2127-2132.	0.4	45

#	Article	IF	CITATIONS
91	Serum Parathyroid Hormone Concentrations Are Increased in Women with Polycystic Ovary Syndrome. Clinical Chemistry, 2005, 51, 1691-1697.	1.5	116
92	Decrease in adiponectin levels in women with polycystic ovary syndrome after an oral glucose tolerance test. Fertility and Sterility, 2005, 83, 232-234.	0.5	17
93	Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary syndrome. Fertility and Sterility, 2005, 84, 538-540.	0.5	39
94	Association of the T45G polymorphism in exon 2 of the adiponectin gene with polycystic ovary syndrome: role of Â4-androstenedione. Human Reproduction, 2004, 19, 1728-1733.	0.4	45
95	Serum resistin levels in women with polycystic ovary syndrome. Fertility and Sterility, 2004, 81, 361-366.	0.5	91
96	Serum adiponectin levels in women with polycystic ovary syndrome. Human Reproduction, 2003, 18, 1790-1796.	0.4	139